6533b823fe1ef96bd127ecd0

RESEARCH PRODUCT

D2-receptor imaging with [123I]IBZM and Single Photon Emission Tomography in psychiatry: a survey of current status

R. SchlösserS. Schlegel

subject

medicine.medical_specialtyReceptor StatusPyrrolidinesNeurologyContrast MediaDrug treatmentDopamine receptor D2Image Processing Computer-AssistedmedicineSingle Photon Emission TomographyHumansPsychiatryBiological PsychiatryBrain ChemistryTomography Emission-Computed Single-Photonmedicine.diagnostic_testReceptors Dopamine D2business.industryBrainHuman brainPsychiatry and Mental healthmedicine.anatomical_structureNeurology123i ibzmPositron emission tomographyBenzamidesDopamine AntagonistsNeurology (clinical)Nuclear medicinebusinessPsychology

description

D2-dopamine receptors can be visualized in the human brain in vivo by Single Photon Emission Tomography (SPECT) and the radiolabeled benzamide [123I]IBZM. The present paper reviews the current status of this type of functional brain imaging with respect to basic methodological aspects, data analysis and quantification. The results from published clinical studies in different psychiatric patient populations and normal controls with [123I]IBZM are reviewed. [123I]IBZM-SPECT is a powerful tool for the investigation of D2-dopamine receptor status in psychiatric disorders, different types of drug treatment as well as therapeutic and side effects of pharmacologic agents. However, there still is a need for standardized imaging times and image-processing procedures. Advantages and disadvantages of SPECT with special regard to Positron Emission Tomography (PET) are also discussed.

yearjournalcountryeditionlanguage
1995-02-01Journal of Neural Transmission
https://doi.org/10.1007/bf01271477